Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta‐analysis of 4 million participants' data

• Published in: CNS neuroscience & therapeutics 2024-08, Vol.30 (8), p.e14888-n/a
• Main Authors: Mady, Abdelrahman, Nabil, Yehia, Daoud, Asma, Alnajjar, Asmaa Zakria, Alsalloum, Taleb, Marwan, Menna, Abdelmeseh, Maickel, Elsayed, Moaz, Krayim, Abdulrahman, Alaa, Mohamed, Masoud, Mahmoud, Bushara, Nagham, Faisal, Roaa, Ahmed, Hayat, Saad, Mohamed, Belabaci, Zineddine, Barrett, Matthew J., Berman, Brian, Negida, Ahmed
• Format: Article
• Language: English
• Subjects: Clinical trials; disease risk; Epidemiology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; hydroxymethylglutaryl‐coenzyme A reductase inhibitors; Keywords; Meta Analysis; Missing data; Movement disorders; Neurodegenerative diseases; Observational studies; Parkinson Disease - drug therapy; Parkinson Disease - epidemiology; Parkinson Disease - prevention & control; Parkinson's disease; Population studies; Risk Reduction Behavior; Software; Statins; Statistical analysis; symptom progression; Systematic review
• ISSN: 1755-5930; 1755-5949; 1755-5949
• DOI: 10.1111/cns.14888

Background Many observational studies have examined the association between statins and the incidence of Parkinson's disease (PD) in high‐risk populations. On the other hand, clinical trials as well as other observational studies investigated the safety and efficacy of statins in slowing disease progression in PD patients. However, the evidence has been inconclusive in both questions. To that end, we conducted this systematic review and meta‐analysis to synthesize evidence on the role of statins in decreasing the risk of PD among high‐risk populations and as a possible disease‐modifying agent for patients with PD. Methods A comprehensive literature search of electronic databases including PubMed, Scopus, Cochrane, and Web of Science has been performed. Relevant studies were chosen and data were extracted and analyzed using RevMan software version 5.4.1. Results Twenty‐five studies (14 cohort, 9 case–control, and 2 randomized controlled trials) have been included in the present systematic review. Of them, 21 studies reported the association between statins and PD risk. Statins were found to significantly reduce the risk of developing PD (pooled RR 0.86, 95% CI [0.77–0.95], p